Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Recently granted patents

New US pharmaceutical patent grants from the past 12 months — competitive surveillance for BD and IP teams.

Patents
890

Quick answer

890 pharmaceutical patents in our USPTO index were granted within the past year. Browse by grant date with links to applicant company portfolios and related drug profiles.

  1. WO 2026114957

    DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT GMBH [DE] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026114918

    DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT GMBH [DE] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026117667

    DOSES DE TITRATION DE MARIDEBART CAFRAGLUTIDE

    AMGEN INC [US] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026115454

    ANTICORPS ANTI-CLAUDINE 18.2, FRAGMENTS DE LIAISON À L'ANTIGÈNE ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS ET MÉTHODES D'UTILISATION DANS UNE THÉRAPIE ANTICANCÉREUSE

    ASTRAZENECA AB [SE] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 20260152488

    AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Jun 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026112045

    NICOTINAMIDES PYRAZOLYLIQUES ET CARBOXAMIDES PYRIMIDINIQUES EN TANT QU'INHIBITEURS DE CAMK2

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 20260146049

    SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026112109

    TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS

    BAYER HEALTHCARE LLC [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026112397

    COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE VIRUS ADÉNO-ASSOCIÉS

    BIOGEN MA INC [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026112047

    AMIDES DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE CAMK2

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026109729

    COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN

    ASTRAZENECA AB [SE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 20260144885

    ANTI-LRRC15 ANTIBODIES AND USES THEREOF

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2026112386

    COMPOSÉS D'OXOISOINDOLINYL PIPÉRIDINE-2,6-DIONE SUBSTITUÉS ET PROCÉDÉS DE DÉGRADATION DE PROTÉINES

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 20260146050

    KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 20260144884

    ANTI-LRRC15 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2026112486

    MÉTHODES DE TRAITEMENT DE L'OBÉSITÉ ET DES AFFECTIONS LIÉES À L'OBÉSITÉ

    AMGEN INC [US] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2026109631

    UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu May 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. AU 2024384453

    CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF

    BASILEA PHARMACEUTICA INTERNATIONAL AG ALLSCHWIL [CH] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2026107418

    DÉRIVÉS DE N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE CAMK2 POUR LE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2026104630

    MÉTHODE DE SÉLECTION DOMINANTE PERMANENTE POUR LA GÉNÉRATION DU VIRUS ANKARA DE LA VACCINE MODIFIÉ RECOMBINANT (MVA)

    BAVARIAN NORDIC AS [DK] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. WO 2026107143

    COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. WO 2026107420

    DÉRIVÉS DE N-(4-(1H-BENZO[D[IMIDAZOL-6-YL)-PYRIDIN-2-YL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    BAYER HEALTHCARE LLC [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. WO 2026107422

    DÉRIVÉS DE 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. WO 2026107424

    DÉRIVÉS DE N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. WO 2026107136

    CONJUGUÉS ANTICORPS ANTI-CEACAM5-MÉDICAMENT POUR LE TRAITEMENT DU CANCER

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. WO 2026106499

    ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES

    BIAL PORTELA & CA SA [PT] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. WO 2026104647

    VACCIN

    ASTRAZENECA AB [SE] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. WO 2026107421

    DÉRIVÉS DE 1H-BENZO[D]IMIDAZOLE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. WO 2026107425

    DÉRIVÉS DE 5-(PYRIDIN-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE UTILES COMME INHIBITEURS DE CAMK2 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. WO 2026099754

    MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. WO 2026102199

    THÉRAPIE COMBINÉE D'UN INHIBITEUR DE PRMT5 ET DU DARAXONRASIB POUR UTILISATION DANS LE TRAITEMENT DU CANCER MTAP-NUL

    AMGEN INC [US] · Granted Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. WO 2026100645

    MÉTHODES DE TRAITEMENT DES SYMPTÔMES VASOMOTEURS CHEZ DES PATIENTES ATTEINTES DE CANCER DU SEIN AVEC LE FÉZOLINÉTANT

    ASTELLAS PHARMA INC [JP] · Granted Fri May 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. EP 4741400

    MULTIMERE MANGANKONTRASTMITTEL

    BAYER AG [DE] · Granted Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue May 08 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. WO 2026093543

    TRAITEMENT COMBINÉ PAR AGONISTE DU GLP1R ET INHIBITEUR DE PCSK9

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. WO 2026093586

    COMBINAISON D'UN INHIBITEUR DE L'ALDOSTÉRONE SYNTHASE (ASI) ET D'UN INHIBITEUR DU CO-TRANSPORTEUR SODIUM-GLUCOSE DE TYPE 2 (SGLT2I) DESTINÉE À ÊTRE UTILISÉE DANS DES MÉTHODES VISANT À RÉDUIRE LE RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES ET D'INSUFFISANCE CARDIAQUE CHEZ UN SUJET

    ASTRAZENECA IRELAND LTD [IE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 20260125398

    5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS

    AMGEN INC [US] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. WO 2026093539

    MÉTHODES DE TRAITEMENT OU DE GESTION DE L'OBÉSITÉ

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. WO 2026093541

    SCHÉMAS POSOLOGIQUES POUR L'AZD5004

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. WO 2026093537

    MÉTHODES DE TRAITEMENT DU DIABÈTE

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. WO 2026094002

    COMBINAISONS DE MOLÉCULES D'ACTIVATION DE LYMPHOCYTES T BISPÉCIFIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE TUMEURS SOLIDES EXPRIMANT CLAUDINE 18.2

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. WO 2026093542

    TRAITEMENT D'ASSOCIATION D'UN AGONISTE DU GLP1R ET D'UN INHIBITEUR DU SGLT-2

    ASTRAZENECA AB [SE] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. WO 2026096847

    MÉTHODES DE RÉGULATION DE L'INFLAMMATION ET DE L'AUTOPHAGIE À L'AIDE DE PIÈGES À LIGANDS ACTRIIB

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu May 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 02 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. WO 2026087531

    FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION

    CASSIOPEA S P A [IT] · Granted Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 20260116870

    NOVEL NAV 1.1 POTENTIATORS

    BOEHRINGER INGELHEIM INT [DE] · Granted Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 20260116972

    CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

    AMGEN RES MUNICH GMBH [DE] · Granted Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 20260115307

    ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Apr 25 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. EP 4732903

    COKRISTALLE VON PITOLISTANTHYDROCHLORID

    BIOPROJET PHARMA [FR] · Granted Wed Apr 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Apr 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How recent are these patent grants?

This hub lists published patents with a grant date within the last 365 days, ordered newest first.

Which patent classes are included?

We index USPTO PatentsView records with pharmaceutical CPC classifications A61K and A61P linked to tracked assignee companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.